Insider Selling: Regina E Groves Unloads $288K Of AtriCure Stock

On September 14, a recent SEC filing unveiled that Regina E Groves, Board Member at AtriCure (NASDAQ:ATRC) made an insider sell.

What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Monday, Groves sold 5,313 shares of AtriCure. The total transaction value is $288,070.

At Tuesday morning, AtriCure shares are down by 0.97%, trading at $55.79.

Get to Know AtriCure Better

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

AtriCure: A Financial Overview

Revenue Growth: AtriCure's remarkable performance in 3 months is evident. As of 30 June, 2026, the company achieved an impressive revenue growth rate of 12.83%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Navigating Financial Profits:

• Gross Margin: The company maintains a high gross margin of 77.23%, indicating strong cost management and profitability compared to its peers.

• Earnings per Share (EPS): With an EPS below industry norms, AtriCure exhibits below-average bottom-line performance with a current EPS of 0.18.

Debt Management: With a below-average debt-to-equity ratio of 0.14, AtriCure adopts a prudent financial strategy, indicating a balanced approach to debt management.

Valuation Overview:

• Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 265.67 suggests caution, as the stock may be overvalued in the eyes of investors.

• Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 4.75 suggests overvaluation in the eyes of investors, considering sales performance.

• EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): With an EV/EBITDA ratio of 71.05, the company's market valuation exceeds industry averages.

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Unmasking the Significance of Insider Transactions

Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.

In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company’s equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.

When a company insider makes a new purchase, that is an indication that they expect the stock to rise.

Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down.

Transaction Codes Worth Your Attention

When it comes to transactions, investors tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of AtriCure's Insider Trades.

This article was generated by Benzinga's automated content engine and reviewed by an editor.